BAX and non-small cell lung carcinoma: Hence, in this study, we hypothesized that BCL2 and BAX polymorphisms, located in the untranslated promoter regions, could be associated with treatment responses and clinical outcomes in advanced NSCLC treated with platinum-based chemotherapy.